| MRNA |
Report |
Q2 Revenue |
MISS |
pred ~$95M vs. cons $105.5M |
MEDIUM |
| MRNA |
Report |
Q2 Operating EPS |
MISS |
pred ~-$1.95 vs. cons -$1.89 |
MEDIUM |
| MRNA |
Report |
Q2 Operating Expenses |
BEAT |
pred ~$885M vs. cons $903.1M |
MEDIUM |
| MRNA |
Guide |
FY2026 Revenue |
UNCHANGED |
guide ~$2.0-2.1B vs. cons $2.088B |
MEDIUM |
| MRNA |
Guide |
FY2026 Cash Cost |
UNCHANGED |
guide ~$4.2B vs. cons UNVERIFIED |
LOW |
| MRNA |
Return |
Day-1 residual (stock − beta × S&P 500) |
-4.0% |
— |
LOW |
| MRNA |
Return |
5-day cumulative residual |
-8.0% (FOLLOW-THROUGH) |
FOLLOW-THROUGH — revenue miss leaves H2 carrying the FY |
LOW |